BOSTON--(BUSINESS WIRE)--IsoRay (AMEX:ISR), a leading-edge developer and provider of brachytherapy seeds for the treatment of prostate cancer and other solid tumors, announced today that the world’s first brachytherapy implants for cancer treatment of the eye using its Cesium-131 seeds were performed at Tufts-New England Medical Center on Wednesday, December 12, 2007. This marks the first time Cesium-131 has been used in an application other than the treatment of prostate cancer.
